News
ALNY ▲ +0.8% - Alnylam Pharmaceuticals, Inc.
ALNY ▲ +0.8% - Alnylam Pharmaceuticals, Inc.
$ALNY Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years
19-NOV-2026 07:02 AM ET
Share this post
More filings for $ALNY
ALNY - Alnylam Pharmaceuticals, Inc. - SEC Filing Update (16-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 16, 2026ALNY - Alnylam Pharmaceuticals, Inc. - SEC Filing Update (13-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 13, 2026ALNY - Alnylam Pharmaceuticals, Inc. - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 5, 2026ALNY - Alnylam Pharmaceuticals, Inc. - SEC Filing Update (30-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 30, 2026ALNY ▼ -4.9% - Alnylam Pharmaceuticals, Inc.Aug 28, 2026ALNY ▼ -4.9% - Alnylam Pharmaceuticals, Inc.Aug 28, 2026
View full $ALNY filing history →💬 Comments
Loading comments…
Leave a comment
